Being a graduate of one of the best faculties in Turkiye, Prof. Huseyin Abali is an experienced medical oncology consultant with a demonstrated history of working in the community, private or university hospitals.
He is the first and current HOD of Medical Oncology at Bahrain Oncology Center, the establishment of which he contributed substantially.
Through years of intense practice added to his education, he has built up a high level of experience in managing different types of cancers from diagnosis to treatment.
Being a caring physician with genuine empathy, he maintained very good communication with patients and families.
Furthermore, through education and practice, he has a good understanding of biostatistics, epidemiology, and clinical trial design in oncology.
Furthermore, he has a substantial experience in multicenter multinational clinical cancer trials from design to writing protocols, to the establishment of clinical trial units, and to the conduct in the field.
In addition, he has experience in scientific publication as an author, reviewer, associate editor and editor-in-chief in an oncology journal (first associate editor and second editor-in-chief of Journal Oncological Sciences-the official journal Turkish Society of Medical Oncology
1 Schmid P et al; KEYNOTE-522 Investigators Pembrolizumab for Early Triple-Negative Breast CancerN Engl J Med 2020 Feb 27;382(9):810-821
2 Schmid P, et al; KEYNOTE-522 Investigators Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer N Engl J Med 2022 Feb 10;386(6):556-567
3 Powles T, et al;KEYNOTE-361 Investigators Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Lancet Oncol 2021 Jul;22(7):931-945
4 Abali H, et al A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study Am J Clin Oncol 2021 Jul 1;44(7):301-307
6 Pivot X, et al PrefHer Study Group Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study Ann Oncol 2014 Oct;25(10):1979-1987
7 Erman M, et alTamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004 Nov;15(11):1622-6
8 Babaoglu et al Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists Clin Pharmacol Ther 2005 Dec;78(6):619-26
9 Abali H et al Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer Chemotherapy 2005 Aug;51(5):280-5